Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries
| Autor: | Ahd Hamidi, Michel Beurret, Hans Kreeftenberg |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Economic growth Capacity Building Haemophilus influenzae type Developing country medicine.disease_cause Haemophilus influenzae Technology Transfer Conjugate vaccine medicine Humans Technology Pharmaceutical Developing Countries Bacterial Capsules Meningitis Haemophilus Haemophilus Vaccines Vaccines Conjugate General Veterinary General Immunology and Microbiology Public health Public Health Environmental and Occupational Health Haemophilus influenzae type b Capacity building Virology Infectious Diseases Technology transfer Molecular Medicine Business Conjugate |
| Zdroj: | Vaccine. 30(33) |
| ISSN: | 1873-2518 |
| Popis: | This paper describes the development of a Haemophilus influenzae type b (Hib) conjugate vaccine at the National Institute for Public Health and the Environment/Netherlands Vaccine Institute (RIVM/NVI, Bilthoven, The Netherlands), and the subsequent transfer of its production process to manufacturers in developing countries. In 1998, at the outset of the project, the majority of the world's children were not immunized against Hib because of the high price and limited supply of the conjugate vaccines, due partly to the fact that local manufacturers in developing countries did not master the Hib conjugate production technology. To address this problem, the RIVM/NVI has developed a robust Hib conjugate vaccine production process based on a proven model, and transferred this technology to several partners in India, Indonesia, Korea and China. As a result, emerging manufacturers in developing countries acquired modern technologies previously unavailable to them. This has in turn facilitated their approach to producing other conjugate vaccines. As an additional spin-off from the project, a World Health Organization (WHO) Hib quality control (QC) course was designed and conducted at the RIVM/NVI, resulting in an increased regulatory capacity for conjugate vaccines in developing countries at the National Regulatory Authority (NRA) level. For the local populations, this has translated into an increased and sustainable supply of affordable Hib conjugate-containing combination vaccines. During the course of this project, developing countries have demonstrated their ability to produce large quantities of high-quality modern vaccines after a successful transfer of the technology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect